GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noile-Immune Biotech Inc (TSE:4893) » Definitions » Total Assets

Noile-Immune Biotech (TSE:4893) Total Assets : 円5,457.0 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Noile-Immune Biotech Total Assets?

Noile-Immune Biotech's Total Assets for the quarter that ended in Mar. 2024 was 円5,457.0 Mil.

During the past 3 years, the average Total Assets Growth Rate was 20.90% per year.

During the past 4 years, Noile-Immune Biotech's highest 3-Year average Total Assets Growth Rate was 20.90%. The lowest was 20.90%. And the median was 20.90%.

Total Assets is connected with ROA %. Noile-Immune Biotech's annualized ROA % for the quarter that ended in Mar. 2024 was -24.22%. Total Assets is also linked to Revenue through Asset Turnover. Noile-Immune Biotech's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.


Noile-Immune Biotech Total Assets Historical Data

The historical data trend for Noile-Immune Biotech's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noile-Immune Biotech Total Assets Chart

Noile-Immune Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Assets
2,674.26 4,271.05 4,641.03 5,778.95

Noile-Immune Biotech Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Assets Get a 7-Day Free Trial Premium Member Only - 6,132.24 6,168.79 5,778.95 5,456.99

Noile-Immune Biotech Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Noile-Immune Biotech's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=5687.452+91.494
=5,778.9

Noile-Immune Biotech's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets=Total Equity (Q: Mar. 2024 )+Total Liabilities (Q: Mar. 2024 )
=5349.775+107.217
=5,457.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Noile-Immune Biotech  (TSE:4893) Total Assets Explanation

Total Assets is connected with ROA %.

Noile-Immune Biotech's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=-1360.708/( (5778.946+5456.992)/ 2 )
=-1360.708/5617.969
=-24.22 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Noile-Immune Biotech's Asset Turnover for the quarter that ended in Mar. 2024 is

Asset Turnover
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=2.587/( (5778.946+5456.992)/ 2 )
=2.587/5617.969
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Noile-Immune Biotech Total Assets Related Terms

Thank you for viewing the detailed overview of Noile-Immune Biotech's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Noile-Immune Biotech (TSE:4893) Business Description

Traded in Other Exchanges
N/A
Address
2-12-10 Shiba-Daimon, Minato-ku, Tokyo, JPN, 105-0012
Noile-Immune Biotech Inc is engaged in the development of novel cancer immunotherapy including CAR-T cell therapy.

Noile-Immune Biotech (TSE:4893) Headlines

No Headlines